187 related articles for article (PubMed ID: 23032737)
1. Acceptability in microbicide and PrEP trials: current status and a reconceptualization.
Mensch BS; van der Straten A; Katzen LL
Curr Opin HIV AIDS; 2012 Nov; 7(6):534-41. PubMed ID: 23032737
[TBL] [Abstract][Full Text] [Related]
2. Adherence to preexposure chemoprophylaxis: the behavioral bridge from efficacy to effectiveness.
Amico KR
Curr Opin HIV AIDS; 2012 Nov; 7(6):542-8. PubMed ID: 22964887
[TBL] [Abstract][Full Text] [Related]
3. State of the science of adherence in pre-exposure prophylaxis and microbicide trials.
Muchomba FM; Gearing RE; Simoni JM; El-Bassel N
J Acquir Immune Defic Syndr; 2012 Dec; 61(4):490-8. PubMed ID: 22932322
[TBL] [Abstract][Full Text] [Related]
4. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice.
Haberer JE
Curr Opin HIV AIDS; 2016 Jan; 11(1):10-7. PubMed ID: 26633638
[TBL] [Abstract][Full Text] [Related]
5. Oral antiretroviral chemoprophylaxis: current status.
Baeten J; Celum C
Curr Opin HIV AIDS; 2012 Nov; 7(6):514-9. PubMed ID: 22964886
[TBL] [Abstract][Full Text] [Related]
6. Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake.
Govender EM; Mansoor LE; Abdool Karim Q
AIDS Care; 2017 Jun; 29(6):734-740. PubMed ID: 27799005
[TBL] [Abstract][Full Text] [Related]
7. Acceptability and adherence of a candidate microbicide gel among high-risk women in Africa and India.
Greene E; Batona G; Hallad J; Johnson S; Neema S; Tolley EE
Cult Health Sex; 2010 Oct; 12(7):739-54. PubMed ID: 20397080
[TBL] [Abstract][Full Text] [Related]
8. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.
Minnis AM; Gandham S; Richardson BA; Guddera V; Chen BA; Salata R; Nakabiito C; Hoesley C; Justman J; Soto-Torres L; Patterson K; Gomez K; Hendrix CW
AIDS Behav; 2013 Feb; 17(2):737-47. PubMed ID: 23065145
[TBL] [Abstract][Full Text] [Related]
9. Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077.
Tolley EE; Zangeneh SZ; Chau G; Eron J; Grinsztejn B; Humphries H; Liu A; Siegel M; Bertha M; Panchia R; Li S; Cottle L; Rinehart A; Margolis D; Jennings A; McCauley M; Landovitz RJ
AIDS Behav; 2020 Sep; 24(9):2520-2531. PubMed ID: 32052214
[TBL] [Abstract][Full Text] [Related]
10. High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.
Carballo-Diéguez A; Balán IC; Brown W; Giguere R; Dolezal C; Leu CS; Marzinke MA; Hendrix CW; Piper JM; Richardson BA; Grossman C; Johnson S; Gomez K; Horn S; Kunjara Na Ayudhya RP; Patterson K; Jacobson C; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Liu A; Mayer KH; Zorrilla C; Lama J; McGowan I; Cranston RD
PLoS One; 2017; 12(7):e0181607. PubMed ID: 28750059
[TBL] [Abstract][Full Text] [Related]
11. Optimizing HIV prevention for women: a review of evidence from microbicide studies and considerations for gender-sensitive microbicide introduction.
Doggett EG; Lanham M; Wilcher R; Gafos M; Karim QA; Heise L
J Int AIDS Soc; 2015; 18(1):20536. PubMed ID: 26700845
[TBL] [Abstract][Full Text] [Related]
12. Acceptability and adherence: findings from a Phase II study of a candidate vaginal microbicide, 'Praneem polyherbal tablet', in Pune, India.
Joglekar NS; Joshi SN; Deshpande SS; Parkhe AN; Katti UR; Mehendale SM
Trans R Soc Trop Med Hyg; 2010 Jun; 104(6):412-5. PubMed ID: 20096909
[TBL] [Abstract][Full Text] [Related]
13. Influences on willingness to use vaginal or oral HIV PrEP during pregnancy and breastfeeding in Africa: the multisite MAMMA study.
van der Straten A; Ryan JH; Reddy K; Etima J; Taulo F; Mutero P; Taylor J; Piper J; Musara P;
J Int AIDS Soc; 2020 Jun; 23(6):e25536. PubMed ID: 32524700
[TBL] [Abstract][Full Text] [Related]
14. Knowledge and Acceptability of HIV pre-exposure prophylaxis (PrEP) among men who have sex with men (MSM) in Ghana.
Ogunbajo A; Leblanc NM; Kushwaha S; Boakye F; Hanson S; Smith MDR; Nelson LE
AIDS Care; 2020 Mar; 32(3):330-336. PubMed ID: 31597455
[TBL] [Abstract][Full Text] [Related]
15. Considerations regarding antiretroviral chemoprophylaxis in MSM.
Poynten IM; Zablotska I; Grulich AE
Curr Opin HIV AIDS; 2012 Nov; 7(6):549-56. PubMed ID: 22918448
[TBL] [Abstract][Full Text] [Related]
16. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study.
Eisingerich AB; Wheelock A; Gomez GB; Garnett GP; Dybul MR; Piot PK
PLoS One; 2012; 7(1):e28238. PubMed ID: 22247757
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous Evaluation of Safety, Acceptability, Pericoital Kinetics, and Ex Vivo Pharmacodynamics Comparing Four Rectal Microbicide Vehicle Candidates.
Leyva F; Fuchs EJ; Bakshi R; Carballo-Dieguez A; Ventuneac A; Yue C; Caffo B; Du Y; Torbenson M; Li L; Mullin G; Lee L; Rohan L; Anton PA; Hendrix CW
AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1089-97. PubMed ID: 26066390
[TBL] [Abstract][Full Text] [Related]
18. Acceptability research on female-controlled barrier methods to prevent heterosexual transmission of HIV: Where have we been? Where are we going?
Elias C; Coggins C
J Womens Health Gend Based Med; 2001 Mar; 10(2):163-73. PubMed ID: 11268299
[TBL] [Abstract][Full Text] [Related]
19. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
[TBL] [Abstract][Full Text] [Related]
20. Acceptability of an "on-demand" pre-exposure HIV prophylaxis trial among men who have sex with men living in France.
Lorente N; Fugon L; Carrieri MP; Andreo C; Le Gall JM; Cook E; Aboulker JP; Capitant C; Molina JM; Spire B
AIDS Care; 2012; 24(4):468-77. PubMed ID: 22085083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
